FDA To Reduce Studies & Testing Of New Drugs For Human Use
The US Food and Drug Administration has announced a sweeping new initiative aimed at speeding experimental drugs from the laboratory into human testing and ultimately toward approval, unveiling measures designed to cut development timelines, reduce information requirements, rely less on traditional animal testing, and accelerate the path to market
The new initiative, called “Operation TrialBlazer”, spans the entire drug-development pipeline—from the earliest stages of development through the clinical trials used to secure FDA approval.
While the agency presents the effort as modernization, the FDA’s own documents repeatedly describe existing requirements, timelines, and testing practices as obstacles that slow products down.
The agency states that the purpose of the initiative is to:
“accelerate and modernize clinical research across the full continuum of drug development—from the Investigational New Drug (IND) phase to late-stage pivotal trials.”
In plain English, the FDA is searching for ways to move drugs from development into human beings faster.
The move comes just days after the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously that the “benefits” of Moderna’s experimental mRNA influenza vaccine, mFlusiva (mRNA-1010), “outweigh its risks,” clearing the way for potential FDA approval in adults aged 50 and older.
Even though Moderna’s own Phase 3 trial confirmed that the shot produced roughly six times more severe reactions than standard-dose influenza vaccines while providing less than one percent in absolute risk reduction.
Members of Congress have warned that the FDA “is not meeting important federal safety requirements to protect its employees and the public while also failing to prioritize scientific data quality delivered from FDA laboratories.”
The developments raise questions about why FDA is simultaneously accelerating drugs through the pipeline while facing accusations that it is already failing to meet basic safety requirements.
Get More Drugs Into More People, Faster
One of the most revealing parts of the new announcement is a proposed Expedited Investigational New Drug pilot program.
According to FDA:
“The proposed Expedited IND pilot program would leverage America’s world-class research institutions as collaborative partners to shorten the time from drug identification to first-in-human study.”
That objective is difficult to misinterpret.
The agency is openly seeking ways to reduce the amount of time between identifying a drug candidate and administering it to human subjects.
Less Data Over Less Time, Not More Data Over More Time
FDA is also targeting the amount of information companies collect before testing products in people.
According to them:
“In the past, some companies have submitted more data than is necessary at that step in the development process, creating unnecessary work that delays promising treatments from reaching early-stage clinical trials.”
The agency says companies should generate and submit “only the data that is needed.”
According to FDA:
“By focusing exclusively on phase-appropriate requirements, companies can save 6 to 12 months of development time.”
That means the FDA believes as much as a year can be removed from the process before products advance further through development.
For Americans who already believe drugs reach the market too quickly, the announcement raises an obvious question: What safeguards, studies, reviews, or information does FDA believe can be eliminated in order to remove six to twelve months from the timeline?
Fast-Track to FDA Approval
The acceleration effort continues into the approval process itself. The FDA simultaneously revised guidance governing what evidence companies may use to support approval.
According to the agency:
“FDA revised this guidance to clarify circumstances in which drug developers may be able to rely on one rigorous, adequate and well-controlled pivotal clinical investigation, plus confirmatory evidence, to demonstrate substantial evidence of effectiveness for drug approval.”
Pivotal trials are the major studies used to support approval decisions.
The revised guidance expands circumstances under which a product may move toward approval based on a single pivotal study combined with other supporting evidence.
According to FDA, these approaches can:
“reduce duplicative infrastructure, streamline data collection, and accelerate the generation of evidence needed to support regulatory decision-making.”
Bottom Line
The documents reveal a coordinated FDA effort to identify every stage of the drug-development process that slows products down and determine whether those steps can be shortened, simplified, replaced, or removed.
The language used throughout the announcement is revealing, with repeated use of terms such as “accelerate,” “shorten,” “reduce,” “streamline,” “flexible,” and “save” development time.
The agency’s most direct admission may be its statement that revised requirements could save sponsors “6 to 12 months of development time.”
For critics who already believe pharmaceutical products are rushed through development without adequate long-term safety evaluation, the announcement is likely to be viewed not as a tightening of standards, but as a government-led effort to move experimental products through the pipeline faster.
With less testing and less safety data.
See more here substack.com
Bold emphasis added
Header image: Sarah Silbiger / Getty Images
Tom
| #
At a time when more studies need to be made and the growth of drugs slowed way down.
Reply
very old white guy
| #
Speed kills. Did they not learn that from the covid vax debacle?
Reply